Incyte reports GVHD cream results; INCA033989 Phase 1 PK study stays active

Two Incyte-linked clinical trial records updated this week, one with posted results and one Phase 1 study still underway.

• A Phase 2 study of topical ruxolitinib 1.5% cream (INCB018424 phosphate) for non-sclerotic chronic cutaneous graft-versus-host disease is listed as completed, with results first posted on 2026-02-10. The study is sponsored by Memorial Sloan Kettering Cancer Center with Incyte Corporation as a collaborator, and patients were prescribed twice daily use of topical ruxolitinib 1.5% cream to a maximum of 20% BSA on each side for 28 ± 3 days¹. Enrollment reached 24 participants¹.
• A Phase 1 study of INCA033989, evaluating pharmacokinetics, safety, and tolerability following subcutaneous or intravenous dosing in healthy adults, is active but not recruiting. The study began on 2026-03-19 and has an estimated primary completion date of 2026-11-14², with enrollment of 108 participants² across seven cohorts testing SC and IV administration, including arms combining the drug with a bioavailability enhancer.